8-K/A: 908 Devices Completes Sale of Desktop Business to Repligen, Releases Pro Forma Financials

908 Devices finalizes the sale of its desktop device portfolio to Repligen Corporation and releases pro forma financial statements reflecting the transaction.

Summary

• 908 Devices Inc. has completed the sale of its desktop device portfolio, known as the Desktop Business, to Repligen Corporation on March 4, 2025.
• The sale included tangible and intangible assets, properties, rights, and assumed contracts related to the Desktop Business, including products like Maverick, Rebel, Maven, Trace C2, and ZipChip.
• Repligen also acquired 100% of 908 Devices GmbH, a wholly-owned subsidiary, and assumed the lease obligation for the North Carolina facility.
• More than fifty employees of 908 Devices transferred to Repligen, and the remaining employees supporting the Desktop Business will be terminated in March 2025.
• 908 Devices and Repligen entered into a supply agreement and a transition services agreement.
• The company will present the Desktop Business as a discontinued operation in its financial statements starting in the first quarter of 2025.
• The unaudited pro forma condensed consolidated balance sheet as of December 31, 2024, and statements of operations for the years ended December 31, 2024 and 2023, reflect the transaction as if it occurred on January 1, 2024.
• The estimated gain on sale is $54.702 million.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The company has completed a strategic sale, which should allow it to focus on core business. The pro forma financials provide clarity on the impact of the sale.

Positives

• The sale provides 908 Devices with an upfront payment of $66.009 million, net of transaction costs.
• The company releases cumulative translation adjustment under 908 Devices GmbH of $1.146 million.
• The transaction allows 908 Devices to streamline its operations and focus on its remaining business segments.
• The company will receive other income from transition services, estimated at $2.3 million for the year ended December 31, 2024.

Negatives

• The company will incur costs related to terminating the remaining employees who were previously supporting the Desktop Business.
• The company will no longer recognize revenues and costs associated with the Desktop Business on an ongoing basis.
• The company paid a bonus to remaining employees of the Company as a result of completing the Transaction, reflecting a $650 thousand adjustment.

Risks

• The actual financial results may differ from the pro forma estimates.
• The utilization of loss carryforwards to offset the taxable gain may be subject to limitations under Internal Revenue Code Section 382.
• The accounting for the gain on the sale of the Desktop Business and adjustments related to the Transaction have not yet been finalized.

Future Outlook

The company will focus on its remaining business segments after the sale of the Desktop Business. The company will present the Desktop Business as a discontinued operation for all periods presented, effective in the first quarter of 2025.

Industry Context

The sale of the Desktop Business to Repligen reflects a strategic decision by 908 Devices to focus on its core competencies and streamline operations. This type of divestiture is common in the life sciences industry as companies seek to optimize their portfolios and allocate resources to high-growth areas.

Comparison to Industry Standards

• Repligen's acquisition of 908 Devices' Desktop Business is similar to other strategic acquisitions in the bioprocessing analytical technology space.
• Companies like Danaher and Thermo Fisher Scientific also actively acquire businesses to expand their product offerings and market reach.
• The financial terms of the deal, including the upfront payment and potential earn-outs, are consistent with industry standards for acquisitions of this type.

Stakeholder Impact

• Shareholders will see a streamlined business with a focus on core competencies.
• Employees of the Desktop Business have transitioned to Repligen.
• Remaining employees of 908 Devices may experience changes in roles and responsibilities.
• Customers of the Desktop Business will now be served by Repligen.

Next Steps

• 908 Devices will present the Desktop Business as a discontinued operation in its financial statements starting in the first quarter of 2025.
• The company will finalize the accounting for the gain on the sale of the Desktop Business and adjustments related to the transaction.

Key Dates